fluorouracil injection usp solution
accord healthcare inc - fluorouracil - solution - 50mg - fluorouracil 50mg - antineoplastic agents
fluorouracil ebewe fluorouracil 5000 mg/100 ml solution for injection vial
sandoz pty ltd - fluorouracil, quantity: 5000 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.
fluorouracil injection 50 mgml
teva pharmaceutical investments singapore pte. ltd. - 5-fluorouracil - injection - 50 mg/ml - 5-fluorouracil 50 mg/ml
benda-5 fu 50 mg/ml solution for injection
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - fluorouracil - solution for injection - fluorouracil 50 mg/ml - antineoplastic agents
fluorouracil injection 50mgml
mylan pharmaceuticals pte. ltd. - fluorouracil - injection, solution - 50mg/ml - fluorouracil 50mg/ml
fluorouracil 250mg/10ml solution for injection vials
pfizer ltd - fluorouracil sodium - solution for injection - 25mg/1ml
5-fluorouracil ebewe 50mg/ml concentrate for solution for infusion
ebewe pharma ges. m.b.h. nfg. kg - fluorouracil - concentrate for solution for infusion - 50mg/ml
5-fluorouracil ebewe 50mg/ml concentrate for solution for infusion
ebewe pharma ges. m.b.h. nfg. kg - fluorouracil - concentrate for solution for infusion - 50mg/ml
fluorouracil injection, solution
accord healthcare, inc. - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 50 mg in 1 ml - fluorouracil is indicated for the treatment of patients with: none. pregnancy category d risk summary there are no adequate and well-controlled studies with fluorouracil in pregnant women. based on its mechanism of action, fluorouracil can cause fetal harm when administered to a pregnant woman. administration of fluorouracil to rats and mice during selected periods of organogenesis, at doses lower than a human dose of 12 mg/kg, caused embryolethality and teratogenicity. malformations included cleft palate and skeletal defects. in monkeys, maternal doses of fluorouracil higher than an approximate human dose of 12 mg/kg resulted in abortion. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus [see clinical pharmacology (12.1)] . animal data malformations including cleft palate, skeletal defects and deformed appendages
fluorouracil - fluorouracil solution
solco healthcare us llc - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 20 mg in 1 ml - fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. in the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. safety and efficacy in other indications have not been established. the diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. with isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. the success rate with fluorouracil solution is approximately 93%, based on 113 lesions in 54 patients. twenty-five lesions treated with the solution produced 1 failure. fluorouracil may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies in pregnant women with either the topical or the parenteral forms of fluorouracil. one birth defect (cleft